Permanent Bar Against Glenmark's Sitagliptin Copies
This article was originally published in Scrip
The Delhi High Court has permanently enjoined Glenmark Pharmaceuticals Ltd from making and selling its generic version of Merck & Co's diabetes therapies Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride). The Indian firm has been found to have infringed the sitagliptin patent.
Register for our free email digests: